AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV CureClinical Research Collaboration Agreement • October 17th, 2018
Barcelona, Spain, 18 October 2018 – AELIX Therapeutics S.L. (“AELIX”), a clinical-stage biotechnology company specialized in the discovery and development of immunotherapies for HIV infection, today announces that it has entered into a clinical research collaboration with Gilead Sciences, Inc. (“Gilead”), a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, to jointly evaluate proprietary investigational products in a strategic clinical study aimed at achieving a functional cure of HIV infection.
Clinical Research Collaboration Agreement Between Awardee and Study SiteClinical Research Collaboration Agreement • October 19th, 2023
This Clinical Research Collaboration Agreement (“Agreement”), is by and between (“Awardee”), a [***drafting note- insert type of organization here, i.e., health care organization***] with a place of business at , and (“Study Site),
AMENDMENT TO CLINICAL RESEARCH COLLABORATION AGREEMENTClinical Research Collaboration Agreement • April 11th, 2014 • Cytodyn Inc • Pharmaceutical preparations
This Amendment (“Amendment”), effective as of the last signature below, hereby amends the Clinical Research Collaboration Agreement (“Agreement”), which was effective November 15, 2012, by and between CYTODYN INC., a Colorado corporation principally located at 1111 Main Street, Suite 660, Vancouver, Washington 98660 (“Company”), and Philadelphia Health & Education Corporation d/b/a DREXEL UNIVERSITY COLLEGE OF MEDICINE, having an office located at 1601 Cherry Street, Suite 10627, Philadelphia, PA 19102 (“Institution”).
CLINICAL RESEARCH COLLABORATION AGREEMENTClinical Research Collaboration Agreement • August 29th, 2013 • Cytodyn Inc • Pharmaceutical preparations • Pennsylvania
This Clinical Research Collaboration Agreement, effective on the last date of signature (“Effective Date”), is by and between CytoDyn, Inc., a Colorado, Corporation principally located at Lake Oswego, Oregon, (“Company”) and Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine, a 501(c)(3) Pennsylvania, nonprofit corporation principally located at 245 N. 15th Street, Philadelphia, PA 19102 (“Institution”). Company and Institution shall herein be individually referred to as “Party” and collectively referred to as “Parties.”
